Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
University of Maryland, Baltimore
Study ID
NCT07620561
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Prurigo Nodularis (PN)

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Lebrikizumab — DRUG
    Participants will receive subcutaneous injections of Lebrikizumab every two weeks for 24 weeks. The first two doses will be 500 mg, and following doses will be 250 mg.

Study Details

The purpose of this study is to evaluate the effectiveness of lebrikizumab in treating adults with moderate-to-severe Prurigo Nodularis (PN).

Key Dates

Start date
Jun 30, 2026
Status verified
May 2026
Primary completion
Dec 31, 2027
Completion
Mar 31, 2028

Study Design

Enrollment
15 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Lebrikizumab
    Participants will receive subcutaneous injections of Lebrikizumab

Primary Outcome Measure

Percent change from baseline in weekly average Peak Pruritus Numeric Rating Scale (PP-NRS) at week 24 [ Time Frame: Baseline; Week 24 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UM Dermatology at UM Professional BuildingBaltimoreMaryland21201
Brandon J Mangracina, MA
[email protected]
732-757-5831
Marie Vidaver, PhD
[email protected]
410-685-1726
Kristin L Khan, MD (PRINCIPAL_INVESTIGATOR)
Carolyn Stolte, CRNP (SUB_INVESTIGATOR)

Find similar trials in Baltimore, MD

By research site
UM Dermatology at UM Professional Building· Baltimore, MD

Related Studies